m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT05495
|
[1] | |||
m6A modification
miR-133a
miR-133a
IGF2BP2
 : m6A sites
Direct
Enhancement
Non-coding RNA
miR-133a
AGO2
lncRNA miRNA circRNA
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) | READER | |||
| m6A Target | miR-133a | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | Non-coding RNA (ncRNA) | ||||
| Epigenetic Regulator | hsa-miR-133a-3p | microRNA | View Details | ||
| Regulated Target | Protein argonaute-2 (AGO2) | View Details | |||
| Crosstalk Relationship | m6A → ncRNA | Enhancement | |||
| Crosstalk Mechanism | m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA | ||||
| Crosstalk Summary | IGF2BP2 physically interacted with Protein argonaute-2 (AGO2) and increased more miR-133a accumulation on its target site.m6A modification promoted the repression of specific miRNA during heart development and hypertrophy. | ||||
| Responsed Disease | Cardiomegaly | ICD-11: BC45 | |||
| Cell Process | Cell proliferation | ||||
In-vitro Model |
CM | Pancreatic insulinoma | Homo sapiens | CVCL_H246 | |
| In-vivo Model | Neonatal mouse cardiomyocytes (CMs) were blinded to isolate from 7-10 cases of postnatal 1-day old wildtype C57/B mice and cultured using Pierce Primary Cardi Page 10.omyocyte Isolation Kit (Thermo Fisher Scientific) as the manufacturer's instructions. | ||||
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
| BC45: Cardiomegaly | 1 Compound(s) Regulating the Disease | Click to Show/Hide the Full List | ||
 Compound Name |
UK-356202 | Clinical trial | [2] | |
|---|---|---|---|---|
| Synonyms |
compound 13j [PMID: 15149680]; UK-356,202
Click to Show/Hide
|
|||
| External Link | ||||
References